ATE288763T1 - Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden - Google Patents
Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides bindenInfo
- Publication number
- ATE288763T1 ATE288763T1 AT00403670T AT00403670T ATE288763T1 AT E288763 T1 ATE288763 T1 AT E288763T1 AT 00403670 T AT00403670 T AT 00403670T AT 00403670 T AT00403670 T AT 00403670T AT E288763 T1 ATE288763 T1 AT E288763T1
- Authority
- AT
- Austria
- Prior art keywords
- pentapetide
- qhnpr
- binding site
- bind specifically
- screening molecules
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00403670A EP1216707B1 (de) | 2000-12-22 | 2000-12-22 | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE288763T1 true ATE288763T1 (de) | 2005-02-15 |
Family
ID=8174003
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00403670T ATE288763T1 (de) | 2000-12-22 | 2000-12-22 | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden |
AT01985936T ATE497390T1 (de) | 2000-12-22 | 2001-12-24 | Neue therapeutische verwendung von smr-1 peptide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01985936T ATE497390T1 (de) | 2000-12-22 | 2001-12-24 | Neue therapeutische verwendung von smr-1 peptide |
Country Status (12)
Country | Link |
---|---|
US (4) | US7153833B2 (de) |
EP (3) | EP1216707B1 (de) |
JP (4) | JP4409831B2 (de) |
CN (2) | CN1217190C (de) |
AT (2) | ATE288763T1 (de) |
AU (2) | AU2002234806A1 (de) |
CA (2) | CA2431913A1 (de) |
DE (2) | DE60018085T2 (de) |
DK (1) | DK1216707T3 (de) |
ES (2) | ES2235806T3 (de) |
PT (1) | PT1216707E (de) |
WO (2) | WO2002051434A2 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
ATE414529T1 (de) | 1999-06-23 | 2008-12-15 | Pasteur Institut | Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
EP1216707B1 (de) * | 2000-12-22 | 2005-02-09 | Institut Pasteur | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
SI1511472T1 (sl) * | 2002-05-29 | 2009-08-31 | Merck & Co Inc | Spojine uporabne pri zdravljenju antraksa in inhibiranju letalnega faktorja |
BRPI0407071B8 (pt) | 2003-01-28 | 2021-05-25 | Ironwood Pharmaceuticals Inc | peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
CN1950354A (zh) * | 2004-05-11 | 2007-04-18 | 默克公司 | N-磺酰化-氨基酸衍生物的制备方法 |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
JP5788788B2 (ja) | 2008-04-07 | 2015-10-07 | アンスティテュ パストゥールInstitut Pasteur | エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体 |
FR2931362B1 (fr) * | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
ES2608050T3 (es) | 2008-12-03 | 2017-04-05 | Synergy Pharmaceuticals Inc. | Formulaciones de agonistas de guanilato ciclasa C y métodos de uso |
US8506544B2 (en) | 2010-06-21 | 2013-08-13 | The Procter & Gamble Company | Disposable absorbent pant with efficient design and convenient single-section side stretch panels |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103764672A (zh) | 2011-03-01 | 2014-04-30 | 辛纳吉制药公司 | 制备鸟苷酸环化酶c激动剂的方法 |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US738778A (en) * | 1903-05-22 | 1903-09-15 | Cottrell C B & Sons Co | Sheet-delivery apparatus for printing and folding machinery. |
ES2058169T3 (es) * | 1987-04-25 | 1994-11-01 | Hoechst Ag | Enkastinas: nuevas glicopeptidos con efecto inhibidor de la encefalinasa, procedimiento para su preparacion y su empleo como preparados farmaceuticos. |
FR2637600B1 (fr) | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5550119A (en) * | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
ATE414529T1 (de) * | 1999-06-23 | 2008-12-15 | Pasteur Institut | Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
EP1216707B1 (de) * | 2000-12-22 | 2005-02-09 | Institut Pasteur | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden |
-
2000
- 2000-12-22 EP EP00403670A patent/EP1216707B1/de not_active Expired - Lifetime
- 2000-12-22 AT AT00403670T patent/ATE288763T1/de active
- 2000-12-22 DE DE60018085T patent/DE60018085T2/de not_active Expired - Lifetime
- 2000-12-22 DK DK00403670T patent/DK1216707T3/da active
- 2000-12-22 ES ES00403670T patent/ES2235806T3/es not_active Expired - Lifetime
- 2000-12-22 PT PT00403670T patent/PT1216707E/pt unknown
-
2001
- 2001-12-24 AU AU2002234806A patent/AU2002234806A1/en not_active Abandoned
- 2001-12-24 US US10/451,064 patent/US7153833B2/en not_active Expired - Lifetime
- 2001-12-24 AU AU2002236100A patent/AU2002236100A1/en not_active Abandoned
- 2001-12-24 EP EP01985936A patent/EP1343520B1/de not_active Expired - Lifetime
- 2001-12-24 JP JP2002552577A patent/JP4409831B2/ja not_active Expired - Fee Related
- 2001-12-24 EP EP01985459A patent/EP1343519A2/de not_active Withdrawn
- 2001-12-24 CA CA002431913A patent/CA2431913A1/en not_active Abandoned
- 2001-12-24 DE DE60143990T patent/DE60143990D1/de not_active Expired - Lifetime
- 2001-12-24 WO PCT/IB2001/002818 patent/WO2002051434A2/en active Application Filing
- 2001-12-24 CA CA2431916A patent/CA2431916C/en not_active Expired - Lifetime
- 2001-12-24 US US10/451,073 patent/US7423020B2/en not_active Expired - Fee Related
- 2001-12-24 AT AT01985936T patent/ATE497390T1/de active
- 2001-12-24 CN CN018212654A patent/CN1217190C/zh not_active Expired - Fee Related
- 2001-12-24 JP JP2002552576A patent/JP4347566B2/ja not_active Expired - Fee Related
- 2001-12-24 WO PCT/IB2001/002819 patent/WO2002051435A2/en active Application Filing
- 2001-12-24 ES ES01985936T patent/ES2363708T3/es not_active Expired - Lifetime
- 2001-12-24 CN CNB018212646A patent/CN1229137C/zh not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/594,105 patent/US7625713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-06 JP JP2008149611A patent/JP2009007352A/ja active Pending
- 2008-11-28 JP JP2008305315A patent/JP2009149633A/ja active Pending
-
2009
- 2009-10-16 US US12/580,701 patent/US20100041072A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE288763T1 (de) | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BR0316438A (pt) | Uso de eritropoietina em doenças cardìacas | |
DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
ATE299860T1 (de) | Vebindungen zur modulation des rage-rezeptors | |
ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
ATE257013T1 (de) | Verwendung von botulinum-toxin zur behandlung von diabetes | |
ATE462427T1 (de) | Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren | |
DE69526437T2 (de) | Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens | |
DE60105144D1 (de) | Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen | |
BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
TR200401669T1 (tr) | Neoplastik hastalıkların tedavisi için metarix-metalloproteinazları önleyen kompozisyon. | |
DE50109156D1 (de) | Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd | |
ATE415962T1 (de) | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs | |
ATE427107T1 (de) | Eine neue verwendung von deferiprone | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
DE60128084D1 (de) | Verwendung von inaktives cln2 proenzym zur behandlung von lincl | |
DE69922174D1 (de) | Biomaterial zur behandlung von zahnfäule | |
ATE337790T1 (de) | Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen | |
EA200100240A1 (ru) | Способ синтеза экзохелина | |
DE60233353D1 (de) | Verfahren zur behandlung von halitose | |
ATE336261T1 (de) | Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen | |
DE50000562D1 (de) | Mittel zur behandlung von pigmentierungsstörungen | |
WO2000050023A3 (en) | Use of tamoxifen and related compounds as CLC3 blockers in the treatment of vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1216707 Country of ref document: EP |